The age range of the study population was 2392 years old
Among these would include mild diarrhea and itching, as well as headaches and nausea
Originally developed by Metabolic Pharmaceuticals in Australia during the 1990s, this synthetic peptide was designed to harness growth hormones fat-mobilizing properties while avoiding the metabolic complications associated with full-length GH therapy
Sadeh, G., Wang, Z., Grewal, J., Rangwala, H., & Price, L
This product is purity-tested for compound identity and is intended for in vitro experimentation, analytical reference, or scientific characterization studies